Crossject Logo

Crossject

Develops emergency medications delivered via a needle-free auto-injector platform.

ALCJ | PA

Overview

Corporate Details

ISIN(s):
FR0004178614 (+6 more)
LEI:
969500W1VTFNL2D85A65
Country:
France
Address:
6 Rue Pauline Kergomard, 21000 dijon

Description

Crossject is a specialty pharmaceutical company focused on developing and commercializing medications for life-threatening emergency situations. The company's core technology is ZENEO®, a proprietary, pre-filled, single-use needle-free auto-injector. This platform is designed to enable patients or untrained caregivers to rapidly, safely, and reliably administer emergency treatments. Crossject's product pipeline targets critical conditions such as epileptic seizures, acute adrenal crisis, and severe allergic reactions (anaphylaxis), aiming to improve patient outcomes by simplifying drug delivery in urgent scenarios.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2015-12-09 08:01
version PDF
French 197.0 KB
2015-12-09 08:01
PDF version
English 190.0 KB
2015-11-06 08:30
version PDF
French 240.5 KB
2015-11-06 08:30
PDF version
English 305.6 KB
2015-10-01 09:50
CROSSJECT : Rapport financier semestriel 2015
French 1.5 MB
2015-09-15 09:12
PDF version
English 117.8 KB
2015-09-14 18:45
version PDF
French 377.0 KB
2015-09-14 18:45
PDF version
English 366.5 KB
2015-07-31 16:30
Publication of the 3rd Letter of shareholders
English 450.6 KB
2015-07-31 16:30
CP 3ème Lettre aux actionnaires
French 265.8 KB
2015-07-23 18:45
CP Crossject dvp L15
French 365.2 KB
2015-07-16 18:35
Version PDF
French 376.3 KB
2015-07-16 18:35
PDF version
English 358.8 KB
2015-07-02 09:30
version PDF
French 719.1 KB
2015-06-11 19:30
Résultat des votes de l’Assemblée générale mixte du 11 juin
French 363.8 KB

Automate Your Workflow. Get a real-time feed of all Crossject filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Crossject

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Crossject via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-06-24 N/A Other Buy 20,000 N/A
2024-06-14 N/A Other Other 10,979 20,289.19 EUR
2024-06-06 N/A Other Other 1,058,617 1,956,324.22 EUR
2024-06-06 N/A Other Other 16,106 29,763.89 EUR
2024-06-06 N/A Other Other 10,275 18,988.20 EUR
2024-06-06 N/A Other Other 10,074 18,616.75 EUR
2024-06-06 N/A Other Buy 5,536 10,230.53 EUR
2023-03-06 N/A Other Other 22,859 75,434.70 EUR

Peer Companies

Advicenne Logo
A specialty pharmaceutical company developing treatments for rare renal diseases.
France
ALDVI
AegirBio AB Logo
A diagnostics company specializing in therapeutic drug monitoring for biological drugs.
Sweden
AEGIR
Aelis Farma Logo
Biopharmaceutical company developing CB1 receptor inhibitors for CNS disorders.
France
AELIS
AEON Biopharma, Inc. Logo
Clinical-stage company developing therapeutic applications for botulinum toxins.
United States of America
AEON
AFC-HD AMS Life Science Co.,Ltd. Logo
An OEM of health foods, supplements, and cosmetics with integrated R&D and manufacturing.
Japan
2927
AGENUS INC Logo
A clinical-stage biotechnology company specializing in immuno-oncology therapies.
United States of America
AGEN
AGIOS PHARMACEUTICALS, INC. Logo
Biopharmaceutical company developing therapies for rare and genetically defined diseases.
United States of America
AGIO
AHN-GOOK PHARMACEUTICAL Co., Ltd. Logo
Develops and markets medicines, focusing on respiratory and cardiovascular treatments.
South Korea
001540
Akari Therapeutics Plc Logo
Develops next-gen antibody-drug conjugates using proprietary cancer-killing toxins.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
A biopharmaceutical company that develops and commercializes therapeutics for kidney disease.
United States of America
AKBA

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.